Real-world sotatercept treatment for pulmonary hypertension

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This observational project collects real-world data on adults with pulmonary hypertension who receive sotatercept at the Mayo Clinic in Rochester, Minnesota. Investigators will record clinical outcomes, safety events, dosing patterns, and tolerability from routine clinic visits and medical records without altering standard care. Participation requires the capacity to provide informed consent and does not introduce experimental interventions. The aim is to describe initial clinical experience to help clinicians understand how sotatercept performs outside of controlled trials.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Adults age 18 or greater who are being treated with sotatercept in the Mayo Pulmonary hypertension clinic.

Exclusion Criteria:

* Adults lacking capacity to consent

Where it's running

• Mayo Clinic
  Rochester, Minnesota, United States Recruiting

Study contacts

• Principal investigator: Robert Frantz, M.D. — Mayo Clinic
• Study coordinator: Hayden Halbach, M.B.A.
• Email: Halbach.Hayden@mayo.edu
• Phone: 507-255-2648

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Levosimendan to see if it helps the heart after PEA in CTEPH

  This small randomized trial tests whether giving levosimendan around surgery helps reduce pulmonary artery pressure and support right heart function after pulmonary endarterectomy for CTEPH.

  Recruiting Meshalkin Research Institute of Pathology of Circulation · Novosibirsk · NCT07914933

• Early treatment with inhaled treprostinil for exercise-induced pulmonary hypertension in ILD or CTD

  This study tests whether inhaled treprostinil added to standard care can improve exercise-related lung blood flow and function in adults with ILD or CTD who develop pulmonary hypertension during exercise.

  Recruiting at 2 sites Early Phase 1 Valley Health System · Paramus, New Jersey and 1 other locations · NCT07837830

• Brazilian Portuguese version of EmPHasis-10 for pulmonary hypertension

  This study tests a Brazilian Portuguese version of the EmPHasis-10 questionnaire to see if it reliably measures quality of life in adults with pulmonary hypertension in Porto Alegre, Brazil.

  Recruiting Hospital de Clinicas de Porto Alegre · Porto Alegre · NCT07822997

• Inhaled mosliciguat for pulmonary hypertension in interstitial lung disease (PH-ILD) patients

  This study tests inhaled mosliciguat versus placebo in people with PH-ILD to see if it helps with their condition.

  Recruiting at 3 sites Phase 3 Pulmovant, Inc. · Kissimmee, Florida and 2 other locations · NCT07816185

• Pulmonary Artery Denervation for Pulmonary Hypertension After M-TEER

  This study tests whether PADN can help people with pulmonary hypertension after M-TEER compared with standard medical therapy.

  Recruiting Early Phase 1 Xiamen Cardiovascular Hospital, Xiamen University · Xiamen, Fujian · NCT07662655

• Risk Factor Assessment for Acute Pulmonary Hypertension Crisis

  This study tests how to identify people with pulmonary hypertension who are at risk of a sudden, life-threatening crisis.

  Recruiting at 4 sites Peking Union Medical College Hospital · Guangzhou, Guangdong and 3 other locations · NCT07653958

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.